News
We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Regeneron Pharmaceuticals, ...
Me’s privacy ombudsman secured court approval to retain WilmerHale in the DNA testing company’s Chapter 11 case despite an ...
When we thought the buyer was Regeneron, I was tentatively optimistic. Yes, a corporation would have your data and intended to profit from it, but that was also true of 23andMe in its heyday.
After the company filed for bankruptcy in March, this week, the sale of 23andMe was completed after previously being approved by a judge.
A bankruptcy court this week approved the $305 million sale of genetics testing firm 23andMe to a nonprofit organization led by the company's former CEO Anne Wojcicki, the company announced. The ...
In response to questions about the lawsuit, Regeneron, which is based in Tarrytown in New York's lower Hudson Valley, noted in a statement that the 23andMe bankruptcy auction has been reopened and ...
23andMe co-founder and CEO Anne Wokcicki won back control of the genetic-test company after a prolonged bankruptcy fight that at one point was won by Regeneron.
"It has always been a sale of DNA to a third party." TTAM Research won a bankruptcy auction for 23andMe’s assets in June, overbidding a $265 million offer from Regeneron Pharmaceuticals (REGN.O).
If nothing changes before the sale of 23andMe is complete, it's up to each individual user to decide if the next buyer gets their genetic data. Selsavage said since the bankruptcy in March, 1.9 ...
A bankruptcy judge approved the sale of 23andMe's assets and business operations to a nonprofit led by 23andMe’s co-founder and former chief executive, Anne Wojcicki.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results